New drugs in the treatment of recurrent or metastatic cervical cancer

Critical Reviews in Oncology/Hematology

Volumn 48, Issue 3, 2003, Pages 323-327

  Savarese, Antonella ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cervical cancer; Chemotherapy; Clinical trials

Indexed keywords

CAMPTOTHECIN; CISPLATIN; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; METASTASIS; PHASE 2 CLINICAL TRIAL; REVIEW; SIDE EFFECT; UTERINE CERVIX CANCER;

EID: 0347623112     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00131-8     Document Type: Review

References (16)

1. Fukuoka M., Noda K., Hasegawa K., Nakajima H., Furuse K., Hirabayashi K., et al. An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II. Gan To Kagaku Ryoho. 23:1996;1813-1824.
2. Schilder R.J., Blessing J.A., Morgan M., Mangan C.E., Rader J.S. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol. Oncol. 76:2000;204-207.
3. Lacava J.A., Leone B.A., Machiavelli M., Romero A.O., Perez J.E., Elem Y.L., et al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J. Clin. Oncol. 15:1997;604-609.
4. Morris M., Brader K.R., Levenback C., et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J. Clin. Oncol. 16:1998;1094-1098.
5. Lhomme C., Vermorken J.B., Mickiewicz E., et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. Eur. J. Cancer. 36:2000;194-199.
6. McGuire W.P., Blessing J.A., Moore D., Lentz S.S., Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group Study. J. Clin. Oncol. 14:1996;792-795.
7. Kudelka AP, Winn R, Edwards CL, et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of cervix. Anticancer Drugs 1997;8:657-61.
8. Bookman M.A., Blessing J.A., Hanjani P., Herzog T.J., Andersen W.A. Topotecan in squamous cell carcinoma of the cervix: a Phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 77:2000;446-449.
9. Verschraegen C.F., Levy T., Kudelka A.P., Llerena E., Ende K., Freedman R.S., et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J. Clin. Oncol. 15:1997;625-631.
10. Lhomme C., Fumoleau P., Fargeot P., Krakowski Y., Dieras V., Chauvergne J. Results of a European organization for research and treatment of cancer/ early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J. Clin. Oncol. 17:1999;3136-3142.
11. Look K.Y., Blessing J.A., Levenback C., Kohler M., Chafe W., Roman L.D. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol. Oncol. 70:1998;334-338.
12. Irvin W.P., Price F.V., Bailey H., et al. A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer. 82:1998;328-333.
13. Burnett A.F., Roman L.D., Garcia A.A., Muderspach L.I., Brader K.R., Morrow C.P. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix. Gynecol. Oncol. 76:2000;63-66.
14. Pignata S., Silvestro G., Ferrari E., et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J. Clin. Oncol. 17:1999;756-760.
15. Peter G.R., Blessing J.A., Gershenson D.M., McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 17:1999;2676-2680.
16. Sugiyama T., Yakushiji M., Noda K., Ikeda M., Kudoh R., Yajima A. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology. 58:2000;31-37.